Showing 6431-6440 of 7509 results for "".
- Xact Nabs Best of Hot Topics at ASAPS 2018https://practicaldermatology.com/news/xact-nabs-best-of-hot-topics-at-asaps-2018/2457727/Cypris Medical, Inc.’s Xact technology took home the “Best of Hot Topics” award at the American Society for Aesthetic Plastic Surgery (ASAPS) meeting in New York. Xact technology is a minimally invasive face and neck lifting suturing d
- Restoration Robotics Launches Continuing Education Master Class for ARTAS Systemhttps://practicaldermatology.com/news/restoration-robotics-launches-continuing-education-master-class-for-artas-system/2457729/Restoration Robotics, Inc. is launching a continuing education Master Class Series for its ARTAS® Robotic Hair Restoration System to train physicians on best practices and the most up-to-date techniques for the technology. The Master Class Series will enable users to provide exceptional
- ThermiVa: First-ever Data Show Vaginal Regenerationhttps://practicaldermatology.com/news/thermiva-first-ever-data-show-vaginal-regeneration/2457730/Thermi’s ThermiVa® device has been shown to deliver significant improvements in common vaginal disorders and improve sexual satisfaction, according to a study published in Dermatologic Surgery. Since it was cleared by the FDA in 2013, ThermiVa has been used
- White Coats, Scrubs Top Patient Preferences for Doctor's Attirehttps://practicaldermatology.com/news/white-coats-scrubs-top-patient-preferences-for-doctors-attire/2457735/What doctors wear matters…a lot, according to the largest-ever study of patient preferences for doctors’ attire. Just more than half of the 4,062 patients surveyed in the clinics and hospitals of ten major medical centers said that what physicians wear is important to th
- Eclipse Announces New Board Membershttps://practicaldermatology.com/news/eclipse-announces-new-board-members/2457740/Meet Eclipse’s Medical and Scientific Advisory Board (M&SAB) for 2018. The 2018 Eclipse M&SAB includes: Dr. Sanjay Batra Dr. Batra obtained his PhD in physiology from the University of Ottawa, C
- PD1 Blocker Shrinks Advanced Squamous Cell Skin Cancershttps://practicaldermatology.com/news/pd1-blocker-shrinks-advanced-squamous-cell-skin-cancers/2457737/A checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of squamous cell carcinoma, an international team reports in the New England Journal of Medicine. “These results mark a potential paradigm shift in the treatment of pa
- Skin Cancer Survey Spotlights Frustration with Perceptions of "Less Serious" Conditionhttps://practicaldermatology.com/news/skin-cancer-survey-spotlights-frustration-with-perceptions-of-less-serious-condition/2457743/People living with skin cancer struggle with perceptions that their condition is less serious than other types of cancer despite significant physical and emotional impact, according to Skin Cancer In America 2018, a national survey by Health Union, LLC of people diagnosed with the condition.
- New Dermatologic Surgery Textbook by McGraw-Hill Enters Second Printing Less Than One Week After Publicationhttps://practicaldermatology.com/news/new-dermatologic-surgery-textbook-by-mcgraw-hill-enters-second-printing-less-than-one-week-after-publication/2457746/McGraw-Hill has just released Jonathan Kantor’s new 1,440-page textbook, Dermatologic Surgery, the most comprehensive and richly illustrated dermatologic surgery textbook ever published, and the first new major multimedia textbook in the field in 13 years. With section editors
- DermTech: Carcinome Clinical Study Enrollment Completehttps://practicaldermatology.com/news/dermtech-carcinome-clinical-study-enrollment-complete/2457745/DermTech, Inc., the global leader in non-invasive molecular dermatology, announced completion of enrollment in the Carcinome™ clinical study. The goal of the Carcinome™ study is to develop a non-invasive genomic test to differentiate basal cell carcinoma (BCC) and squamous cell
- FDA Approves Cimzia for Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-cimzia-for-moderate-to-severe-plaque-psoriasis/2457747/The FDA has approved extending the label for UCB's Cimzia (certolizumab pegol) to include a new indication in adults with moderate to severe plaque psoriasis. Cimzia is indicated for the treatment of adults with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy